

Coexistence in the Same Family of Both Focal and Diffuse Forms of Hyperinsulinism

VASSILI VALAYANNOPOULOS, MD¹
 MARTINE VAXILLAIRE, PHD²
 YVES AIGRAIN, MD, PHD³
 FRANCIS JAUBERT, MD, PHD⁴
 CHRISTINE BELLANNÉ-CHANTELLOT, MD⁵
 MARIA-JOAO RIBEIRO, MD, PHD⁶

FRANCIS BRUNELLE, MD, PHD⁷
 PHILIPPE FROGUEL, MD, PHD^{2,8}
 JEAN-JACQUES ROBERT, MD, PHD⁹
 MICHEL POLAK, MD, PHD⁹
 CLAIRE NIHOU-L-FÉKÉTÉ, MD, PHD³
 PASCALE DE LONLAY, MD, PHD¹

Neonatal hyperinsulinism is the most important cause of hypoglycemia in infancy (1,2). The inappropriate oversecretion of insulin is responsible for profound hypoglycemia, requiring aggressive treatment to prevent brain damage (1–3). Neonatal hyperinsulinism is often resistant to medical therapy (1–4), and pancreatectomy is required for many sufferers (1,5–6). The histopathological lesions associated with neonatal hyperinsulinism may be described as diffuse or focal (7–8). Focal adenomatous islet cell hyperplasia is sporadic and has been demonstrated to arise in individuals who have a germline mutation in the paternal allele of the sulfonylurea receptor 1 ABCC8 gene (9,10) or the inward-rectifying potassium channel Kir6.2 (KCNJ11) (10) in addition to a somatic loss of the maternally derived chromosome region 11p15 in adenomatous pancreatic β -cells (9–11). Diffuse hyperinsulinism may be familial and arises from the autosomal recessive inheritance of mutations in both ABCC8 (12) and KCNJ11 (13–14) genes. The therapeutic outcome for the patients is heavily dependent on distinguishing between the two histopathological lesions. Diffuse hyperinsulinisms, which are unresponsive to medical treatment, require extensive pancreatectomy, with a high risk of diabetes

(5,15–16). Conversely, focal hyperinsulinism can be cured by limited pancreatectomy (6,17). Genetic counseling is dramatically different, as focal hyperinsulinism is considered a sporadic molecular event with a very low recurrence risk (10,18), while diffuse hyperinsulinism is inherited in a recessive pattern for neonatal onset forms (12–14,19) and in dominant or sporadic transmission for late-onset hyperinsulinism (19). We present here the first case of coexistence of both focal and diffuse neonatal hyperinsulinism in the same consanguineous family with a dramatically different treatment and outcome.

RESEARCH DESIGN AND METHODS

The first child, a boy, of a consanguineous couple (first cousins) of Portuguese ancestry (Fig. 1) presented at birth with an increased weight and body length. He presented with hypoglycemic seizures during the first day of life. Repeated hypoglycemic (ranging from 1.7 to 2.3 mmol/L, reference range >2.7) were found during the 1st month, associated with high insulin levels (ranging from 5.5 to 18 mU/L, reference range <0.4 in hypoglycemia) consistent with the diagnosis of persistent neonatal hyperinsulinism. Medical treatment with diazoxide and somatostatin along with

high-glucose dietary treatment failed to control hypoglycemia. A transhepatic pancreatic catheterization with venous sampling of glucose, insulin, and C-peptide, as previously described (17), revealed hypersecretion of insulin in the lower part of the pancreatic body. Via pancreatic surgery with a preoperative histological analysis, a focal lesion of 15 mm of diameter on the lower part of the pancreatic body was identified.

The second child, a girl, also suffered from neonatal hypoglycemic seizures. Treatment by diazoxide, nifedipin, and injection of somatostatin was not successful, and the child was infused with high doses of glucose ($15 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{mn}^{-1}$) and continuous infusion of glucagon (2 mg/day). An ^{18}F -fluoro-L-DOPA positron emission tomography study was performed, showing a diffuse uptake of the radiotracer in the pancreatic area, compatible with a diffuse form of hyperinsulinism.

RESULTS — A limited pancreatectomy fully cured the first child, who, now 6 years old, is healthy with no relapse of hypoglycemia. Loss of 11p15 heterozygosity of maternal origin was found in the lesion with positive proinsulin staining in β -cells (Fig. 1A) and absence of expression of the p57 protein (Fig. 1B). A paternally inherited heterozygous mutation of the ABCC8 gene (G228D) was also identified. The maternal genotype was not tested. As focal hyperinsulinism is sporadic, reassuring genetic counseling was given in another center.

On the second child, a near-total pancreatectomy was performed after a peroperative histological confirmation of the diffuse form (Fig. 1C), and the child developed signs of diabetes requiring insulin injections a few weeks after surgery. Moreover, the child acquired neurological impairment with psychomotor retardation due to repeated hypoglycemic seizures, with brain atrophy on the magnetic resonance imaging scan. Molecular analysis of the ABCC8 gene displayed a homozygous mutation identical to the one found in the first child at the heterozygous form. Both parents were found heterozygous for this mutation (Fig. 1).

From the ¹Department of Metabolic Disorders, Hôpital Necker-Enfants Malades, Paris, France; the ²Lille Institute of Biology, Lille, France; the ³Department of Pediatric Surgery, Hôpital Necker-Enfants Malades, Paris, France; the ⁴Department of Pathology, Hôpital Necker-Enfants Malades, Paris, France; the ⁵Department of Biology, Hôpital Saint-Antoine, Paris, France; the ⁶Service Hospitalier Frédéric Joliot, Orsay, France; the ⁷Department of Radiology, Hôpital Necker-Enfants Malades, Paris, France; the ⁸Department of Genomic Medicine⁸, Hammersmith Hospital, Imperial College, London, U.K.; and the ⁹Department of Endocrinology, Hôpital Necker-Enfants Malades, Paris, France.

Address correspondence and reprint requests to Vassili Valayannopoulos, Department of Metabolic Disorders, Hôpital Necker-Enfants Malades, 149, Rue des Sèvres, 75015 Paris, France. E-mail: vassili.valaya@nck.aphp.fr.

Received for publication 25 November 2006 and accepted in revised form 13 March 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 23 March 2007. DOI: 10.2337/dc06-2327.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.




Figure 1—Pedigree of a consanguineous couple with two children presenting with hyperinsulinism. Both parents are heterozygous for the G228D mutation (half-black symbol) on the *ABCC8* gene. The first child is heterozygous like his parents but developed a focal form of hyperinsulinism. The focal lesion has been confirmed by histology, showing positive proinsulin staining (A). P57, a maternal-origin protein, is not expressed on the focal lesion (B). The second child is homozygous for the G228D mutation (full black symbol) and has diffuse hyperinsulinism, confirmed by histological examination, showing positive proinsulin staining in all surgical samples taken from different parts of the pancreas (C).

CONCLUSIONS— We present here the first report on both focal (sporadic) and diffuse (familial) forms of hyperinsulinism occurring in the same family and showing well-characterized genetic patterns. In the first child, a paternally inherited *ABCC8* mutation associated with a loss of the maternal wild-type chromosome in the pancreatic lesion was responsible for the focal lesion. Paternal and maternal mutations in the *ABCC8* gene due to consanguinity were responsible for the recurrence of hyperinsulinism in the second child, with a diffuse pattern. Recent estimations from France, Japan, and the U.S. suggested that 40–65% of all hyperinsulinism patients have a focal form (20,21). Usually, genetic counseling in cases of focal hyperinsulinism is reassuring, as the paternally inherited *ABCC8* mutation and the loss of the maternal 11p15 allele in the pancreatic cells are two independent genetic events. Indeed, loss of 11p15 heterozygosity may be regarded as the “second hit” according to Knudson’s model, based on the paradigm of retinoblastoma (22), whereas the germline, inherited mutation may be regarded as the “first hit”. However, unlike mutations of genes involved in-cell growth or DNA repair, the germline *ABCC8* mutation is not expected to trigger the “second hit,” unless by chance. Thus, the rate of somatic mutation (loss of 11p15 maternal allele) and, consequently, the risk of having another child with a focal form remains low. By contrast, in this consanguineous family, the risk of occurrence of a diffuse form of hyperinsulinism was 25%, as the risk for the offspring to be the carrier of a heterozygous mutation was 50%. The global risk for recurrence of hyperinsulinism in this family,

focal or diffuse, was finally equal to the risk of relapse of a diffuse form.

In conclusion, this familial presentation confirms the possibility of the occurrence of focal hyperinsulinism in consanguineous families. Genetic counseling should be prudent in consanguineous families and should include molecular screening for both parents, regardless of the histological form of hyperinsulinism.

References

1. Stanley CA: Hyperinsulinism in infants and children. *Ped Clin North Am* 44:363–374, 1997
2. Bruining GJ: Recent advances in hyperinsulinism and the pathogenesis of diabetes mellitus. *Current Opinion in Pediatrics* 2:758–765, 1990
3. Thomas CG Jr, Underwood LE, Carney CN, Dolcourt JL, Whitt JJ: Neonatal and infantile hypoglycemia due to insulin excess: new aspects of diagnosis and surgical management. *Ann Surg* 185:505–517, 1977
4. Touati G, Poggi-Travert F, Ogier de Baulny H, Rahier J, Brunelle F, Nihoul-Fekete C, Czernichow P, Saudubray JM: Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. *Eur J Pediatr* 157:628–633, 1998
5. Shilyanski J, Fisher S, Cutz E, Perlman K, Filler RM: Is 95% pancreatectomy the procedure of choice for treatment of persistent hyperinsulinemic hypoglycemia of the neonate? *J Pediatr Surg* 32:342–346, 1997
6. Thornton PS, Alter CA, Levitt Katz LE, Baker L, Stanley CA: Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. *J Pediatr* 123: 637–643, 1993
7. Goossens A, Gepts W, Saudubray JM, Bonnefont JP, Nihoul-Fekete C, Heitz PU, Kloppel G: Diffuse and focal nesidioblastosis: a clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. *Am J Surg Pathol* 3:766–775, 1989
8. Rahier J, Fält K, Müntefering H, Becker K, Gepts W, Falkmer S: The basic structural lesion of persistent neonatal hypoglycaemia with hyperinsulinism: deficiency of pancreatic D cells or hyperactivity of B cells? *Diabetologia* 26:282–289, 1984
9. Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Maternal allele loss with hyperinsulinism: deficiency of the paternally inherited mutation of the *SUR1* gene leads to congenital hyperinsulinism in focal islet cell adenomatous hyperplasia of the pancreas. *J Clin Invest* 102:1286–1291, 1988
10. Fournet JC, Mayaud C, de Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in *ABCC8* or *KCNJ11*. *Am J Pathol* 158:2177–2184, 2001
11. de Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. *J Clin Invest* 100:802–807, 1997
12. Nestorowicz A, Wilson BA, Schoor KP,

- Inoue H, Glaser B, Landau H, Stanley CA, Thornton PS, Clement JP 4th, Bryan J, Aguilar-Bryan L, Permutt MA: Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. *Hum Mol Genet* 5:1813–1822, 1996
13. Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. *Hum Mol Gen* 5:1809–1812, 1996
14. Nestorowicz A, Inagaki N, Gono T, Schoor KP, Wilson BA, Glaser B, Landau H, Stanley CA, Thornton PS, Seino S, Permutt MA: A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. *Diabetes* 46:1743–1748, 1997
15. Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission : high incidence of diabetes mellitus and persistent b-cell dysfunction at long-term follow-up: *J Clin Endocrinol Metab* 80:386–392, 1995
16. Labrune P, Lechevallier S, Rault M, Odièvre M: Diabetes mellitus 14 years after subtotal pancreatectomy for neonatal hyperinsulinism. *J Pediatr Surg* 25:1246–1247, 1990
17. Lyonnet S, Bonnefont JP, Saudubray JM, Nihoule-Fekete C, Brunelle F: Localisation of focal lesion permitting partial pancreatectomy in infants (Letter). *Lancet* 2:671, 1989
18. Sempoux C, Guiot Y, Rahier J: The focal form of persistent hyperinsulinemic hypoglycemia of infancy. *Diabetes* 50 (Suppl.1):S182–S183, 2001
19. Fournet JC, Junien C: Genetics of congenital hyperinsulinism. *Endocr Pathol* 15: 233–240, 2004
20. Tanizawa Y, Matsuda K, Matsuo M, Ohta Y, Ochi N, Adachi M, Koga M, Mizuno S, Kajita M, Tanaka Y, Tachibana K, Inoue H, Furukawa S, Amachi T, Ueda K, Oka Y: Genetic analysis of Japanese patients with persistent hyperinsulinemic hypoglycemia of infancy: nucleotide-binding fold-2 mutation impairs cooperative binding of adenine nucleotides to sulfonylurea receptor 1. *Diabetes* 49:114–120, 2000
21. Stanley CA: Advances in diagnosis and treatment of hyperinsulinism in infants and children (Letter). *J Clin Endocrinol Metab* 87:4857–4859, 2002
22. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 68:820–823, 1971